HIGH DOSE ACYCLOVIR VERSUS VIDARABINE IN NEONATAL HERPES SIMPLEX INFECTION

本研究的具体目的是：1）确定大剂量阿昔洛韦与阿糖腺苷治疗是否可以进一步降低CNS或播散性新生儿HSV感染的急性和长期随访的发病率和死亡率。2)为了确定高剂量阿昔洛韦化疗在新生儿中是否安全和耐受，将监测以下内容- a）宿主功能的生化和骨髓参数（SGOT、BUN、肌酸酐、CBC分类、血小板计数和尿分析）。 B）宿主抗体应答（通过ELISA测定的总HSV抗体和针对特异性抗体的抗体） 多肽）。 c）急性和长期随访的不良影响。3)确定是否对抗病毒药物产生耐药性4）扩大新生儿HSV感染婴儿的疾病分类，以预测预后5）确定高剂量阿昔洛韦与维巴利定治疗的病毒排泄模式是否发生变化6）确定CSF中HSV糖蛋白特异性抗原和抗体是否可预测长期神经系统结局7）确定CSF中的特异性抗原和抗体是否在治疗后较晚出现，并指示脑中病毒的潜伏性再激活。

Specific objectives of this study are: 1) To determine whether high-dose acyclovir vs. vidarabine therapy can further decrease morbidity and mortality of CNS or disseminated neonatal HSV infection both acutely and on long-term follow-up. 2) To determine if high dose acyclovir chemotherapy is safe and tolerated in the newborn, the following will be monitored- a) biochemical and bone-marrow parameters of host function (SGOT, BUN, creatinine, CBC with differential, platelet count, and urinalysis). b) host antibody response (total HSV antibodies by ELISA and antibodies to specific polypeptides.) c) Adverse effects both acutely and on long-term follow-up. 3) To determine if resistance to antiviral medication develops 4) To amplify disease classification for babies with neonatal HSV infection for purposes of predicting prognosis 5) To determine whether there is a change in viral excretion patterns in high-dose acyclovir vs. vibaridine therapy 6) To determine whether antigens and antibodies specific for HSV glycoproteins within the CSF predict long-term neurologic outcome 7) To determine whether specific antigens and antibodies in the CSF appear late after treatment and are indicatiove of insidious reactivation of virus in the brain.